TY - JOUR
T1 - Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer
AU - Zlotta, Alexandre R.
AU - Roumeguere, Thierry
AU - Kuk, Cynthia
AU - Alkhateeb, Sultan
AU - Rorive, Sandrine
AU - Lemy, Anne
AU - Van Der Kwast, Theodorus H.
AU - Fleshner, Neil E.
AU - Jewett, Michael A S
AU - Finelli, Antonio
AU - Schulman, Claude
AU - Lotan, Yair
AU - Shariat, Shahrokh F.
AU - Nortier, Joelle
PY - 2011/6
Y1 - 2011/6
N2 - Background: More than 25% of bladder cancer (BC) cases are still muscle-invasive at first diagnosis. Screening is unproven to enable the detection of more non-muscle-invasive tumors. BC association with aristolochic acid nephropathy (AAN) was reported after intake of slimming pills containing Chinese herbs. Objective: We evaluated whether a BC screening protocol in a high-risk and unique patient population had an impact on the stage of tumor presentation. Design, setting, and participants: Forty-eight AAN-affected patients were enrolled in a screening program, establishing BC incidence during prospective screening cystoscopies and biopsies biannually for up to 10 yr. Two patients were lost to follow-up, and three refused screening after consenting. Measurements: Patients were evaluated for presence of BC and tumor stage at diagnosis. Results and limitations: BC was diagnosed in 25 patients (52%). Among 43 patients who underwent screening cystoscopies (median follow-up: 94 mo), 22 were first diagnosed with non-muscle-invasive BC but none with muscle-invasive tumors and none died of BC. Three women who declined follow-up were diagnosed and died with advanced metastatic disease. The limitations of our findings include the small sample size of this case series, the absence of a real control group, and the particular risk factor in these patients that differs from the usual risk factors, such as smoking or industrial chemicals. Conclusions: BC screening in high-risk groups may allow identification of tumors before muscle invasion. The optimal screening schedule and the relevance of the present findings in smoking-related BC remain to be defined.
AB - Background: More than 25% of bladder cancer (BC) cases are still muscle-invasive at first diagnosis. Screening is unproven to enable the detection of more non-muscle-invasive tumors. BC association with aristolochic acid nephropathy (AAN) was reported after intake of slimming pills containing Chinese herbs. Objective: We evaluated whether a BC screening protocol in a high-risk and unique patient population had an impact on the stage of tumor presentation. Design, setting, and participants: Forty-eight AAN-affected patients were enrolled in a screening program, establishing BC incidence during prospective screening cystoscopies and biopsies biannually for up to 10 yr. Two patients were lost to follow-up, and three refused screening after consenting. Measurements: Patients were evaluated for presence of BC and tumor stage at diagnosis. Results and limitations: BC was diagnosed in 25 patients (52%). Among 43 patients who underwent screening cystoscopies (median follow-up: 94 mo), 22 were first diagnosed with non-muscle-invasive BC but none with muscle-invasive tumors and none died of BC. Three women who declined follow-up were diagnosed and died with advanced metastatic disease. The limitations of our findings include the small sample size of this case series, the absence of a real control group, and the particular risk factor in these patients that differs from the usual risk factors, such as smoking or industrial chemicals. Conclusions: BC screening in high-risk groups may allow identification of tumors before muscle invasion. The optimal screening schedule and the relevance of the present findings in smoking-related BC remain to be defined.
KW - Bladder cancer
KW - Muscle invasion
KW - Screening
KW - Stage
UR - http://www.scopus.com/inward/record.url?scp=79955601707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955601707&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2011.03.027
DO - 10.1016/j.eururo.2011.03.027
M3 - Article
C2 - 21458152
AN - SCOPUS:79955601707
SN - 0302-2838
VL - 59
SP - 1026
EP - 1031
JO - European urology
JF - European urology
IS - 6
ER -